Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jacqueline Barkley

Physician Assistant Camillus, NY Physician Assistant

NPI 1891025946 CMS profile 10871286

5417 W Genesee St Ste 3, Camillus, NY 13031

Open in the dashboard

General payments

$4,418

266 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jacqueline Barkley of Camillus, NY is reported in the CMS Open Payments database as having received $4,418 across 266 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,023 48
2024 General $1,060 54
2023 General $1,066 71
2022 General $1,194 92
2021 General $75 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jacqueline Barkley
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jacqueline Barkley were reported at $1,023. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jacqueline Barkley Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $75 $132 $37–$438 $132
2022 $1,194 $155 $48–$522 $149
2023 $1,066 $167 $52–$557 $160
2024 $1,060 $178 $55–$600 $164
2025 $1,023 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,145 83 payments
  2. Novo Nordisk Inc $524 37 payments
  3. AstraZeneca Pharmaceuticals LP $470 9 payments
  4. Lilly USA, LLC $311 19 payments
  5. Janssen Pharmaceuticals, Inc $284 13 payments
  6. GlaxoSmithKline, LLC. $279 20 payments
  7. Pfizer Inc. $177 11 payments
  8. Amgen Inc. $161 9 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $146 13 payments
  10. Merck Sharp & Dohme Corporation $97 6 payments
  11. Other $822 46 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,418 266 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $516 39 payments
  2. Ozempic $370 21 payments
  3. QULIPTA $360 25 payments
  4. RYBELSUS $356 20 payments
  5. BREZTRI $283 4 payments
  6. UBRELVY $256 19 payments
  7. SPRAVATO $175 6 payments
  8. TRELEGY ELLIPTA $172 12 payments
  9. JARDIANCE $164 11 payments
  10. AIRSUPRA $158 3 payments
  11. Other $3,140 190 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 100 drugs

Part D claims

3,566

Median for Physician Assistant: 241

Drug cost

$354,601

Median for Physician Assistant: $4,110

Branded share of claims

21.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 64 $84,018
Ozempic Semaglutide Brand 55 $76,421
Trulicity Dulaglutide Brand 23 $39,436
Mounjaro Tirzepatide Brand 26 $29,218
Eliquis Apixaban Brand 16 $18,514
Januvia Sitagliptin Phosphate Brand 12 $14,238
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 13 $13,065
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 15 $11,774
Repatha Sureclick Evolocumab Brand 12 $8,652
Farxiga Dapagliflozin Propanediol Brand 11 $6,321

The 10 drugs with the highest cost, of 100 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$26,052

Of which drugs: $1,566

Medicare patients

104

Average age 73

Services billed

530

66 women, 38 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 40%
Diabetes 29%
Ischemic heart disease 23%
Cancer 19%
Depression 19%
Atrial fibrillation 18%
Chronic kidney disease 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 12 12 $982

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $282
$282 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $92
$92 — —
UBRELVY
  • AbbVie, Inc. $59
$59 — —
ZEPBOUND
  • Lilly USA, LLC $52
$52 — —
RYBELSUS
  • Novo Nordisk Inc $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

266 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record